Thrombosis Research
Volume 124, Issue 4 , Pages 403-408 , September 2009

Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer

  • Raffaele Palmirotta

      Affiliations

    • Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163 Rome, Italy
    • ,
  • Patrizia Ferroni

      Affiliations

    • Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163 Rome, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 06 66130425; fax: +39 06 66130407.
    • ,
  • Annalisa Savonarola

      Affiliations

    • Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163 Rome, Italy
    • ,
  • Francesca Martini

      Affiliations

    • Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163 Rome, Italy
    • ,
  • Filippo Ciatti

      Affiliations

    • Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163 Rome, Italy
    • ,
  • Anastasia Laudisi

      Affiliations

    • Medical Oncology, Department of Internal Medicine, University of Rome “Tor Vergata”, Tor Vergata Clinical Center, Viale Oxford 81, 00133 Rome, Italy
    • ,
  • Valentina Sini

      Affiliations

    • Medical Oncology, Department of Internal Medicine, University of Rome “Tor Vergata”, Tor Vergata Clinical Center, Viale Oxford 81, 00133 Rome, Italy
    • ,
  • Girolamo Del Monte

      Affiliations

    • San Raffaele Rocca di Papa, via Ariccia 16, 00040, Rocca di Papa, Rome, Italy
    • ,
  • Fiorella Guadagni

      Affiliations

    • Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163 Rome, Italy
    • ,
  • Mario Roselli

      Affiliations

    • Medical Oncology, Department of Internal Medicine, University of Rome “Tor Vergata”, Tor Vergata Clinical Center, Viale Oxford 81, 00133 Rome, Italy

Received 28 July 2008 ,Revised 3 February 2009 ,Accepted 17 February 2009.

References 

  1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1–22
  2. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost. 2005;93:631–640
  3. Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer. 2004;5:348–352
  4. Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost. 2004;91:450–456
  5. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94:116–128
  6. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001;93:913–920
  7. Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Kruger A, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 2002;62:4617–4622
  8. Sternlicht MD, Dunning AM, Moore DH, Pharoah PD, Ginzinger DG, Chin K, et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomark Prev. 2006;15:2107–2114
  9. Castello R, Espana F, Vazquez C, Fuster C, Almenar SM, Aznar J, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res. 2006;117:487–492
  10. Minisini AM, Fabbro D, Loreto CD, Pestrin M, Russo S, Cardellino GG, et al. Markers of the uPA System and Common Prognostic Factors in Breast Cancer. Am J Clin Pathol. 2007;128:112–117
  11. Zhang X, Shu XO, Cai Q, Ruan Z, Gao YT, Zheng W. Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival. Clin Cancer Res. 2006;12:6037–6042
  12. Lei H, Hemminki K, Johansson R, Altieri A, Enquist K, Henriksson R, et al. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer. Breast Cancer Res Treat. 2008;109:165–175
  13. Blasiak J, Smolarz B. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. Acta Biochim Pol. 2000;47:191–199
  14. Balogh GA, Russo IH, Russo J. Mutations in mismatch repair genes are involved in the neoplastic transformation of human breast epithelial cells. Int J Oncol. 2003;23:411–419
  15. Lewis MR, Callas PW, Jenny NS, Tracy RP. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost. 2001;86:1495–1500
  16. Solè X, Guinò E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22:1928–1929
  17. Chung HC, Rha SY, Park JO, Yoo NC, Kim JH, Roh JK, et al. Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Breast Cancer Res Treat. 1998;49:41–50
  18. Blann AD, Gurney D, Wadley M, Bareford D, Stonelake P, Lip GY. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis. 2001;12:43–50
  19. Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, et al. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep. 2005;14:235–239
  20. Dittardi R, Meo S, Fabris F, Gasparini G, Contri D, Medici M, et al. Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers. 2001;16:87–96
  21. Alvarez-Millán JJ, Bocos C, Ferrín V, Lucas AR, Ruibal A, Schneider J. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells. Oncology. 2002;62:286–290
  22. Eroglu A, Ulu A, Cam R, Akar N. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer. J BUON. 2006;11:481–484
  23. Zhang W, Yu YY. Polymorphisms of short tandem repeat of genes and breast cancer susceptibility. Eur J Surg Oncol. 2007;33:529–534
  24. Luqmani YA, Mathew M. Allelic variation of BAT-25 and BAT-26 mononucleotide repeat loci in tumours from a group of young women with breast cancer. Int J Oncol. 2004;25:771–775
  25. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867

☆ Presented at the 4th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC), Bergamo, 26-28 October, 2007.

PII: S0049-3848(09)00128-5

doi: 10.1016/j.thromres.2009.02.014

Thrombosis Research
Volume 124, Issue 4 , Pages 403-408 , September 2009

Article Tools

* Image Usage & Resolution